MI/26/20 Associate Scientist

Key Details

Job ID:
MI/26/20
Role:
Associate Scientist
Salary:
£45,000 – £60,000 per annum, dependent upon experience
Closing date:
14th June 2026

About the role

We seek a motivated and ambitious individual to work alongside us to deliver an internationally recognised CRUK core funded programme in Small Cell Lung Cancer (SCLC) discovery research. This career defining opportunity offers research independence, national and international visibility and leadership responsibility. The Associate Scientist will play a pivotal role in shaping and delivering our strategic vision to improve the treatment of this aggressive lung cancer.

Working closely with Group leads Prof Caroline Dive and Dr Kathryn Simpson, the post holder will contribute to our research strategy. You will supervise staff and students to deliver ongoing SCLC biology projects and develop your own ideas to attract new funding and initiate and lead new projects. You will author publication outputs and represent the Group at National and International Conferences. You will also become a member of the CRUK Lung Cancer Centre of Excellence.

About you

You will have a PhD in cancer biology, molecular and/or cell biology, molecular pharmacology or a related discipline and relevant experience in a cancer research laboratory. Our ideal candidate will have a strong track record in basic discovery cancer research, (ideally in lung and/or neuroendocrine cancers) with proven cell and molecular biology and/or pharmacology skills including experience working with a range of in vivo preclinical models. Extensive post-doctoral experience gained in academia and/or the biotechnology/Pharma sectors, together with extensive experience in studying tumour biology, including function testing studies (e.g. CRISPR, degrons, screening), are essential for the role. You will be a proactive problem solver who relishes a challenge. With experience in supervising early career researchers and in manuscript and grant writing, you will be pivotal to the success of research projects within the SCLC Biology Group and the maintenance of our international reputation in the field of SCLC research. You will enjoy teamwork and gain satisfaction from both personal and team success.

Caroline Dive Director & Senior Group Leader
Paterson Building Scientific Administration

More information

Professor Caroline Dive

Caroline is Director of the aligned CRUK National Biomarker Centre, with research spanning tumour biology, preclinical pharmacology, biomarker discovery, biomarker assay validation and clinical qualification to regulatory standards, bioinformatics, biostatistics and most recently, digital clinical trials. Caroline is also a Senior Group Leader, jointly running the Small Cell Lung Cancer Biology group with Kathryn Simpson at the CRUK Manchester Institute. From 2021 to 2025, Caroline was also Interim Director of the Manchester Institute.

Small Cell Lung Cancer (SCLC) Biology Group

Small Cell Lung Cancer (SCLC) Biology Group is an aggressive neuroendocrine (NE) cancer, with early metastasis (frequently to liver and the brain) and a poor prognosis. Most patients are initially highly sensitive to chemotherapy but disease relapse with acquired chemoresistance is rapid and the introduction of immune checkpoint inhibitors benefits only a minority of patients. A more complete understanding of SCLC biology is needed to deliver effective, personalised therapies and vulnerabilities of molecular subtypes are revealing new therapeutic strategies. Our biobank of >65 extensively charcterised circulating Tumour Cell-derived patient explant models (CDX) mimic the donor’s disease, display intra-tumour heterogeneity, span the molecular subtypes and metastasise to the sites seen in patients1-6. These models are used in our studies of tumour plasticity, chemoresistance and metastasis and are complemented using immune competent models. We work closely with the adjacent CRUK National Biomarker Centre to develop liquid biopsies7 (CTCs and ctDNA) and tissue biomarkers to uplift SCLC clinical trials. Our established partnership with the Christie Foundation NHS Trust facilitates validation of findings in preclinincal models in clinical specimens. Our group makes use of the latest in vitro and in vivo techniques and technologies and a wide variety of bioinformatics approaches to interrogate the increasingly appreciated complexity of SCLC biology, with the goal of identifying novel treatment targets and biomarkers to facilitate the implementation of precision medicine programs. 1Hodgkinson et al., Nature Medicine (2014); 2Simpson et al, Nature Cancer (2020); 3Schenk et al., Nat Comms (2021); 4Williamson et al., Nature Comms (2016)5Pearsall et al., J Thorac Oncol (2023);6Catozzi et al., Cell Reports (2025);7Chemi et al, Nature Cancer, 2022.

About CRUK Manchester Institute

Our aim is to understand the fundamental basis of cancer and apply that knowledge to developing new treatment strategies for cancer patients. Our advanced research programmes span a spectrum of cancer research, from the molecular and cellular basis of cancer through to drug discovery, translational research and clinical trials. rnThe Institute has access to outstanding laboratory facilities and exceptional core services, including next generation sequencing, microarrays, confocal microscopy, bioinformatics, histology and mass-spectrometry.

Professor Caroline Dive
Small Cell Lung Cancer (SCLC) Biology Group
About CRUK Manchester Institute

How to apply

To apply for this position please complete the online application via ‘Apply Now’. Please ensure you detail the names of three referees and ensure you submit your application before the closing date specified.

For any informal enquiries about this post, please contact: Prof Caroline Dive: caroline.dive@cruk.manchester.ac.uk or Dr Kathryn Simpson: kathryn.simpson@cruk.manchester.ac.uk

Closing date:  18:00 hours on 14th June 2026.

First stage Interview: 29th June 2026.

Contact us for further information

Enter your full name
Enter your email address
Type your question here

Why choose Cancer Research UK Manchester Institute?

The Cancer Research UK Manchester Institute, an Institute of The University of Manchester, is a world-leading centre for excellence in cancer research. The Institute is core funded by Cancer Research UK (www.cancerresearchuk.org),
the largest independent cancer research organisation in the world.

We are partnered with The Christie NHS Foundation Trust, one of the largest cancer treatment centres in Europe, which is located adjacent to the CRUK MI Manchester Institute in South Manchester. These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes.

Careers that have a lasting impact on cancer research and patient care

We are always on the lookout for talented and motivated people to join us.  Whether your background is in biological or chemical sciences, mathematics or finance, computer science or logistics, use the links below to see roles across the Institute in our core facilities, operations teams, research groups, and studentships within our exceptional graduate programme.

Gloved hands filling a stripette white lab coat

Latest from CRUK MI

Cancer Research In the Paterson Building

Find out more about the facilities across the Institute

Leukaemia Immunology & Transplantation

The Leukaemia Immunology and Transplantation laboratory aim to develop a comprehensive strategy to prevent post-transplant relapse in patients treated with allogeneic haematopoietic stem cell transplantation – the only curative therapy for many patients with acute myeloid leukaemia (AML) and other poor-risk haematological malignancies.

Patient derived preclinical models reveal novel biology of SCLC

Immune detection of dying tumour cells can elicit cancer immunity when the host permits it

Cancer Research In the Paterson Building
Leukaemia Immunology & Transplantation
Patient derived preclinical models reveal novel biology of SCLC